Cargando…
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials
BACKGROUND: The severe forms of asthma represent a major burden, because of severity of symptoms, costs and impact on everyday life. Recently, Mepolizumab (MEP) was approved and marketed for the treatment of hypereosinophilic severe asthma. This anti-IL-5 monoclonal antibody reduced exacerbation rat...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282342/ https://www.ncbi.nlm.nih.gov/pubmed/30555618 http://dx.doi.org/10.1186/s40413-018-0210-7 |